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Abstract  Gadolinium-enhanced  magnetic  resonance  for  the  evaluation  of  hepatic  lesions  is
increasingly  being  used  in  clinical  practice,  especially  in  patients  with  suspicious  focal  lesions,
whether benign  or  malignant.  In  regard  to  hepatocellular  carcinoma,  the  diagnostic  per-
formance  of  magnetic  resonance  through  the  «conventional» protocols  and  multi-detector
computerized  tomography  consisting  of  multiphase  evaluation  with  intravenous  contrast,
largely depends  on  the  size  of  the  lesion.  They  are  more  reliable  in  lesions  >  2  cm.  However,
in lesions  measuring  1-2  cm,  establishing  the  deﬁnitive  diagnosis  is  a  real  challenge,  with  sen-
sitivity values  of  45-65%,  but  generally  with  excellent  speciﬁcity  (>  95%).  Furthermore,  if  the
lesion has  a  diameter  <  1  cm,  diagnosis  is  usually  unreliable.  In  these  last  2  settings,  the  comple-
mentary use  of  liver-speciﬁc  contrast  agents  can  be  advantageous.  The  aim  of  our  article  was
to review  the  current  evidence  on  the  usefulness  of  this  new  non-invasive  diagnostic  method  in
hepatic lesions.
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Resonancia  magnética  con  ácido  gadoxético  ----contraste  hepatoespecíﬁco---- para  la
evaluación  de  lesiones  focales
Resumen  La  resonancia  magnética  con  gadolinio  para  la  evaluación  de  lesiones  hepáticas
es un  método  cada  vez  más  utilizado  en  la  práctica  clínica,  particularmente  para  pacientes
con lesiones  focales  sospechosas,  ya  sean  benignas  o  malignas.  En  el  caso  del  carcinoma
hepatocelular,  el  rendimiento  diagnóstico  de  la  resonancia  magnética  a  través  de  protocolos
«convencionales» y  mediante  la  tomografía  computarizada  multidetector,  que  consiste  en  la
evaluación  de  múltiples  fases  con  contraste  intravenoso,  depende  en  gran  medida  del  taman˜o
de la  lesión,  considerándose  más  certero  en  lesiones  >  2  cm.  Sin  embargo,  para  aquellas  lesiones
de 1-2  cm,  el  establecimiento  de  un  diagnóstico  deﬁnitivo  es  un  verdadero  reto,  con  valores
de sensibilidad  del  45-65%,  aunque  por  lo  general  con  una  excelente  especiﬁcidad  (>  95%).
Además,  si  la  lesión  tiene  un  diámetro  <  1  cm,  el  diagnóstico  es  generalmente  poco  ﬁable.  En
estos 2  últimos  escenarios,  el  uso  complementario  de  medios  de  contraste  hepatoespecíﬁcos
puede ser  útil.  El  objetivo  de  este  artículo  es  revisar  la  evidencia  actual  de  la  utilidad  de  este
nuevo método  de  diagnóstico  no  invasivo  en  las  lesiones  hepáticas.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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adolinium-enhanced  magnetic  resonance  (MR)  for  the  eval-
ation  of  hepatic  lesions  is  being  increasingly  used  in  clinical
ractice,  particularly  in  those  patients  suspected  of  having
ocal  lesions,  either  benign  or  malignant.
With  respect  to  hepatocellular  carcinoma  (HCC),  the
pithelial  tumor  whose  incidence  is  on  the  rise  and  that
urrently  holds  5th  place  in  frequency,  the  diagnostic
erformance  of  the  so-called  ‘‘conventional’’  MR  and  mul-
idetector  computed  tomography  (MDCT)  protocols  that
onsist  of  multiphase  evaluations  with  intravenous  contrast,
argely  depends  on  the  size  of  the  lesion.  Both  imaging
odalities  are  considered  reliable  and  they  have  a  sensi-
ivity  of  100%  if  the  lesions  are  larger  than  2  cm.1--4
However,  establishing  an  accurate  diagnosis  for  those
esions  between  1-2  cm  is  a  real  challenge,  particularly  in
atients  with  cirrhosis,  80%  of  whom  present  with  HCC  and
hose  annual  incidence  of  this  type  of  lesion  is  2-8%.5--7 The
ensitivity  values  are  44-47%  for  lesions  of  1-2  cm1-4 and  29-
3%  for  those  that  measure  less  than  1  cm.2--4 In  tumors  with
 diameter  under  1  cm,  diagnosis  is  generally  unreliable.
his  scenario  is  increasingly  more  frequent  due  to  the  use
f  ultrasound  as  the  initial  primary  screening  method  rec-
mmended  by  the  majority  of  the  guidelines.6,8--10 In  lesions
easuring  1-2  cm  and  under  1  cm  and  in  lesions  regarded  as
ndetermined  after  analysis  with  conventional  strategies,
he  complementary  use  of  liver-speciﬁc  (LS)  contrast  agents
n  MR  could  be  useful.
The  aim  of  the  present  manuscript  was  to  review  the
urrent  evidence  on  the  emerging  role  of  LS  contrast  agents
n  the  evaluation  of  focal  lesions,  especially  in  HCC,  and
o  describe  their  main  differential  diagnoses.  According  to
he  literature,  these  agents  appear  to  be  the  most  sensitive
ethod  for  HCC  detection,  increasing  sensitivity  values  by
-15%.11--13
i
s
tiver-speciﬁc contrast agents: types and
roperties
 simple  way  to  classify  the  contrast  agents  employed  in
R  is  by  dividing  them  into  2  large  groups:  1)  non-LS  and
)  LS.  The  ‘‘traditional’’  media  belong  to  the  ﬁrst  group,
ased  on  chelating  agents  of  gadolinium,  whose  typical
ehavior  is  intravascular  and  extracellular.  On  the  other
and,  the  liver-speciﬁc  contrast  media,  which  consist  of
uperparamagnetic  iron  oxide  particles  (ferumoxides),  are
ubdivided  into  those  that  are  taken  up  by  Kupffer  cells  and
hose  that  are  taken  up  by  functional  hepatocytes.  The  lat-
er  are  compounds  that  are  also  based  on  gadolinium,  called
adobenate  dimeglumine  (Gd-BOPTA)  and  gadoxetic  acid
Gd-EOB-DTPA).  They  are  considered  intravascular,  extracel-
ular,  and  intrahepatic  contrast  agents  and  are  the  topic  of
he  present  work.
Hepatocytes  take  up  less  Gd-BOPTA  (3-5%)  than  gadoxetic
cid  (50%)  and  both  agents  are  excreted  without  changes
nto  the  biliary  tract.14 In  the  case  of  biliary  tract  obstruc-
ion,  there  is  an  increase  in  their  renal  excretion.  The
ntracellular  step  depends  on  the  expression  of  the  mem-
rane  receptors  called  multidrug-resistant  protein  3  (MRP
)  and  MRP  4  and  the  organic  anion  transporter  polypeptide
 (OATP8),  also  known  as  1B1/B3,  located  in  the  basolateral
inusoidal  membrane  that  borders  the  sinusoid  and  the
pace  of  Disse,  whereas  the  MRP2  transporter,  located  in
he  canalicular  membrane,  is  in  charge  of  excreting  the
ontrast  medium  into  the  bile  canaliculus14 (Fig.  1).
These  types  of  LS  agents  behave  similarly  to  the
‘traditional’’  contrast  agents  during  the  arterial,  portal,
nd  venous  phases.  In  other  words,  they  allow  the  perfusion
f  the  lesion  to  be  evaluated,  which  is  an  indispensible
maging  element  for  establishing  the  differential  diagno-
is.  However,  the  real  additional  diagnostic  effect  that
hese  contrast  agents  offer,  requires  images  in  a  delayed
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Figure  1  Liver-speciﬁc  contrast  medium  action  mechanism.
The liver-speciﬁc  agent  is  introduced  into  the  hepatocyte
through  the  organic  anion  transporter  polypeptide  (OATP1,
B1/B3)  and  exits  through  the  ATP-dependent  multidrug-
resistant  proteins  (MRP2,  MRP3,  MRP4)  located  in  the  sinusoidal
membrane.  MRP2  is  regulated  through  membrane  recovery
(reduced  bile  outlet  ﬂow)  or  introduction  (increased  outlet
ﬂow), and  ﬁnally,  the  liver-speciﬁc  agent  is  not  metabolized
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ArterialPlain T1
T1 in-phaseT2
Figure  2  Small-size  hepatocellular  carcinoma.  A  60-year-old  woma
lobulation and  nodularity,  as  well  as  heterogeneous  signal  intensity  o
MDCT (not  shown).  Top  row: Note  the  rounded  lesion  in  segment  7,  
of-phase, and  with  restricted  diffusion  (DWI).  Bottom  row: In  the  LA
in the  arterial  phase  with  rapid  washout  in  the  portal  venous  phase
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hase  (15-25  min),  called  the  hepatobiliary  phase.  It  is  the
ime  that  is  needed  for  the  medication  to  become  concen-
rated  inside  the  functional  hepatocyte.15--18 That  is  to  say,
 classic  MR  protocol  for  evaluating  the  focal  lesion  would
nclude  the  T1  dual  echo  conventional  sequences  (in-phase
nd  out-of-phase),  T2  with  and  without  fat  saturation,  3D
holangiography,  multiphase  contrasted  T1  (plain,  arterial,
ortal,  venous,  and  delayed  for  2-3  min),  diffusion,  and  in
ddition,  a  T1  in  the  hepatobiliary  phase,15 a  protocol  lasting
pproximately  50  min.
adoxetic acid usefulness in the evaluation of
igh-grade dysplastic nodules and
epatocellular carcinoma
he  use  of  this  type  of  contrast  agent  enables  lesions  that
ontain  hepatocytes  to  be  distinguished  from  those  that
o  not.  As  a  result,  malignant  lesions  composed  of  non-
unctioning  hepatocytes  (high-grade  dysplastic  nodules  and
CC)  or  that  have  no  hepatocytes  (metastasis)  do  not  show
ptake  of  this  type  of  contrast  in  the  hepatobiliary  phase
Fig.  2).  Likewise,  these  agents  also  have  been  used  to
istinguish  focal  nodular  hyperplasia  from  ﬁbrolamellar  car-
inoma  and  from  hepatic  adenoma,  2  benign  lesions  with
ifferent  treatment  and  follow-up  strategies.19
These  contrast  media  could  be  especially  useful  in  those
atients  with  hepatic  lesions  that  do  not  have  the  ‘‘classic’’
ascular  behavior  of  HCC.  The  typical  characteristics  that
20 minVenous
DWIT1 out-of-phase
n  whose  liver  has  changes  from  cirrhosis  with  important  contour
f  the  parenchyma,  and  a  lesion  that  was  undetermined  through
isointense  on  T2  and  hypointense  on  T1  both  in-phase  and  out-
VA  sequence  dynamic  phases  there  is  important  enhancement
 -notice  the  enhancement  of  the  rest  of  the  parenchyma-  and
ich  are  characteristic  ﬁndings  of  hepatocellular  carcinoma.
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eﬁne  HCC  in  a  dynamic  or  multiphase  MR  study  after  intra-
enous  contrast-enhancement  according  to  the  guidelines
f  the  American  Association  for  the  Study  of  Liver  Diseases
AASLD)  are:  1)  a  hypervascular  lesion  during  the  arterial
hase,  and  2)  washout  of  the  contrast  agent  during  the
enous  phase  or  the  appearance  of  capsule  if  there  is  no
ashout;  the  latter  is  not  contemplated  in  the  guidelines
espite  its  having  great  diagnostic  speciﬁcity  (Fig.  2).19--21
his  behavior  is  highly  suggestive  of  HCC  with  speciﬁcity
alues  above  95%,  but  with  sensitivity  of  45-65%  in  lesions
easuring  1-2  cm  in  diameter.8,22 Nevertheless,  the  absence
f  ‘‘classic’’  vascular  characteristics  occurs  relatively  fre-
uently  due  to  the  fact  that  during  hepatocarcinogenesis--a
omplex  and  gradual  process  of  epigenetic  and  genetic  alter-
tions  in  the  transformation  of  malignant  hepatic  cells  to
CC--it  is  recognized  that  the  vascular  support  of  the  lesion
aries.  It  encompasses  a  spectrum  in  which  ﬁrst,  there  is
 predominance  of  portal  vascular  ﬂow  due  to  the  greater
umber  of  portal  triads  and  a  lower  grade  of  ‘‘normal’’  arte-
ial  ﬂow,  as  occurs  with  the  regeneration  nodules.  Then,
here  ends  up  being  an  output  that  is  100%  arterial  from
he  ‘‘abnormal’’  vessels,  due  to  the  null  or  lower  density  of
he  portal  triads  and  the  greater  density  of  both  the  sinu-
oids  with  capillarization  and  the  unpaired  arteries;  in  other
ords,  those  arteries  that  are  not  associated  with  the  por-
al  triads,  as  occurs  in  poorly  differentiated  HCC,  that  show
 typically  arterial  enhancement  and  a  portal  and  venous
ashout.20,23 In  addition,  within  this  spectrum  there  are
esions  with  scant  portal  ﬂow,  as  well  as  a  mixture  of  nor-
al  and  abnormal  arterial  output,  and  it  is  here  where  some
esions  are  found  that  are  considered  high-grade  dysplas-
ic  nodules  and  early  stage  HCC  (microinvasive),  also  called
n  situ  carcinoma.  The  majority  are  under  2  cm  in  diame-
er  and  both  are  difﬁcult  to  detect  through  conventional
ethods.20,23 Therefore,  the  high-grade  dysplastic  nodules,
s  well  as  early  stage  HCC,  can  appear  atypical,  being  hyper-
ascular  in  the  arterial  phase,  although  without  washout  in
he  portal  or  venous  phases,  or  with  an  absence  of  arterial
ascularity  and  its  presence  in  later  phases.  Hence,  the  gen-
ral  sensitivity  of  MR  with  conventional  contrast  agents  is
nly  62%.19 In  regard  to  these  types  of  lesions,  if  LS  contrast
gents  were  to  be  used  and  if  the  lesion  were  hypointense  in
he  20  min  phase,  strict  surveillance  of  the  lesion,  or  biopsy
f  HCC  were  highly  suspected,  would  be  the  steps  to  follow.
n  other  words,  in  the  hepatobiliary  phase,  the  contrast
edium  is  not  concentrated  in  these  lesions  because  they
ack  functioning  hepatocytes,  differentiating  them  from  the
erilesional  liver  that  has  greater  signaling  intensity  due  to
he  intracellular  presence  of  the  LS  contrast  agent.
LS  contrast  agents  are  being  employed  in  the  diagnosis  of
igh-grade  dysplastic  nodules  and  early  stage  HCC  because
here  is  recent  evidence  suggesting  that  the  expression
f  the  transporters  in  charge  of  introducing  these  con-
rast  media  into  the  cell  diminishes  during  the  process  of
epatocarcinogenesis,  before  the  typical  sequential  changes
n  the  abovementioned  tumor  vascularity  occur.  Reduced
ATP8  transporter  expression  can  be  partly  attributed  to  the
xpression  of  the  3  beta  nuclear  factor  of  the  hepatocyte, transcription  factor  that  is  overexpressed  in  HCC  and  that
epresses  OATP8  transcription.15
Therefore,  the  potential  indications  for  the  use  of  LS  con-
rast  agents  would  be  in  those  patients  with  lesions  larger
d
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han  2  cm  that  are  considered  undetermined  after  conven-
ional  analysis  through  tomography  or  magnetic  resonance
ith  non-LS  contrast  media,  and  initially  in  lesions  smaller
han  2  cm  that  are  frequently  undetermined  after  following
aid  strategies.
vidence of  gadoxetic acid usefulness in the
valuation of focal lesions and hepatocellular
arcinoma
n  accordance  with  initial  series,  the  diagnostic  performance
f  LS  contrast-enhanced  MR  for  establishing  the  diagno-
is  of  high-grade  dysplastic  nodules  or  well  differentiated
CC  in  lesions  previously  considered  undetermined  signif-
cantly  improves,  compared  with  conventional  strategies,
ith  sensitivity  and  speciﬁcity  values  of  82-99%  and  70-95%,
espectively.19,24--26 The  hypointense  behavior  of  a  lesion  in
he  hepatobiliary  phase  is  regarded  as  a sign  that,  together
ith  the  rest  of  the  conventionally  evaluated  characteris-
ics,  improves  the  overall  test  performance.  In  a  study  by
im  et  al.  on  96  patients  with  116  nodules  of  1-2  cm  in  diam-
ter,  in  which  LS  contrast-enhanced  MR  was  compared  with  a
athologic  reference  standard  and/or  18-month  follow-up,
he  sensitivity  of  the  radiologic  signs  considered  diagnos-
ic  was  67%  (CI:  51-79%),  according  to  the  guidelines  of
he  AASLD.  It  improved  up  to  84%  (CI:  70-92%)  when  the
ypointensity  on  T1  in  the  hepatobiliary  phase  and/or  the
yperintensity  of  the  lesion  on  the  T2  sequences  were  added
o  these  radiologic  signs.19 In  another  study  on  62  patients
ith  83  HCCs  that  compared  the  diagnostic  performance  of
ultiphase  MDCT  and  LS  contrast-enhanced  MR  vs  pathol-
gy  (surgical  resection),  no  overall  signiﬁcant  difference  was
bserved  between  the  imaging  methods.24 However,  in  the
ubgroup  of  lesions  <  1  cm,  a  signiﬁcant  difference  in  sensi-
ivity  was  observed  (70%  vs  30-50%,  p  <  0.05).
In  a  study  on  34  explanted  patients  with  102  hepatic  nod-
les,  none  of  the  32  low-grade  dysplastic  nodules  showed
ypointense  behavior  in  the  hepatocellular  phase,  unlike
he  HCCs  in  which  only  1  tumor  out  of  40  showed  no  typi-
al  hypointense  behavior  in  that  phase.27 The  results  of  this
tudy  coincide  with  those  observed  in  several  studies  during
ollow-up  of  non-hypervascular  nodules  in  the  arterial  phase
nd  with  hypointensity  in  the  hepatocellular  phase,  in  which
he  accumulative  rate  of  typical  HCC  development  varied
rom  15-35%  at  one  year  and  up  to  46%  at  2  years,  mainly  in
esions  greater  than  1  cm.28--30 These  results  have  motivated
ome  medical  associations  to  incorporate  the  use  of  LS  con-
rast  agents  in  their  diagnostic  algorithms  as  evidence  to
e  followed,  once  any  abnormality  is  detected  in  the  initial
tudies  (ultrasound  or  high  tumor  marker  level).31,32
However,  it  should  be  taken  into  account  that  5-12%
f  HCCs  and  close  to  30%  of  high-grade  dysplastic  nodules
re  not  hypointense  in  the  LS  contrast-enhanced  hepatic
hases,  and  there  can  even  be  a  greater  accumulation  of
ontrast  medium  in  the  hepatobiliary  phase.14,16,24,30 This
nding  is  possibly  due  to  the  paradoxical  overexpression
f  the  OATP8  genes  and  to  the  absence  of  functional  bile
ucts  or  the  transporter  outlet  membrane  in  some  tumors,
n  which  case  a  different  cellular  origin  or  genetic  alter-
tions  during  hepatocarcinogenesis  are  contemplated.14,33
istologically,  the  majority  of  these  tumors  are  moderately
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20 minVenousArterialPlain T1
Out-of-phaseIn-phaseDWIT2
Figure  3  Hemangioma.  A  56-year-old  woman  with  an  ultrasound  ﬁnding  of  a  hepatic  focal  lesion  in  segment  8.  Top  row:  Nodular
lesion with  lobulated  contours,  hyperintense  on  T2,  with  important  restricted  diffusion,  and  hypointense  on  T1  in  the  images  both
in-phase and  out-of-phase.  Bottom  row:  note  the  typical  peripheral  nodular  enhancement  from  the  arterial  phase  with  progressive
centripetal  ﬁll-in  on  the  venous  phase  -signal  intensity  similar  to  the  rest  of  the  parenchyma-  and  hypointensity  on  the  20  min
delayed phase,  characteristics  of  cavernous  hemangioma.
20 minVenousArterial 10 min
Out-of-phasePlain T1DiffusionT2
Figure  4  Focal  nodular  hyperplasia.  A  42-year-old  woman  with  focal  lesions  in  segments  6  and  7  undetermined  through  ultra-
sound and  computed  tomography.  The  distinction  between  adenoma  vs  focal  nodular  hyperplasia  is  relevant  due  to  their  different
management.  Top  row:  Isointense  nodular  lesion  on  T2  with  hyperintense  central  scar  in  the  diffusion  (DWI)  and  isointense  to  the
rest of  the  parenchyma  on  T1  with  no  signal  decay  in  the  out-of-phase  sequence.  Bottom  row:  In  the  dynamic  sequences  with
gadoxetic acid,  the  lesion  presents  enhancement  starting  from  the  arterial  phase.  The  20  min  equilibrium  and  hepatobiliary  phases
show behavior  similar  to  the  rest  of  the  parenchyma,  calling  attention  to  the  presence  of  a  hypointense  central  scar  that  has  no
hepatocytes. These  data  are  typical  of  focal  nodular  hyperplasia.
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Table  1  Important  characteristics  for  differentiating  the  most  frequent  hepatic  lesions  through  the  use  of  liver-speciﬁc  contrast
agents.
Lesions  Clinical
characteristics
Pre-contrast-
enhancement  MR
characteristics
Behavior  with  the  liver-speciﬁc  contrast  agent
Arterial  phase  Portal  venous
phase
Equilibrium
phase
Hepatobiliary
phase
Hemangioma  Most  common
benign  hepatic
lesion
Hyperintense  on  T2  Peripheral
nodular
enhancement
Peripheral  nodular
enhancement  with
a  centripetal
tendency
Iso  or
hypointense
Hypointense
FNH 2nd  most  common
neoplasia
Reproductive  age
women
Isointense  in  relation
to the  liver
parenchyma  Central
scar  Hyperintense  on
T2
Hyperintense
(in  ‘‘wagon
wheel’’)
Isointense  Isointense  Iso  or
hyperintense
Adenoma Reproductive  age
women
Use  of  OCPs
Various  subtypes
Heterogeneous  on  T1
(due to  hemorrhage
or intralesional  fat)
Variable  Variable  Variable  Hypo  or
hyperintense
Metastasis Appearance
similar  to  primary
tumor
Hypo  or
hypervascular
Hypo  (ring
enhancing)  or
hyperintense
Hypointense  (ring
enhancing)
Hypointense  Hypointense
OCPs: oral contraceptives; FNH: focal nodular hyperplasia.
Sources: Cogley and Miller,40 van Kessel et al.,41 Purysko et al.,42 Grazioli et al.43
Plain T1  VenousArterial 20 min
DWIT2  In-phase  Out-of-phase
Figure  5  Adenoma.  A  40-year-old  woman  with  a  focal  lesion  in  segment  6  observed  through  ultrasound.  It  was  not  possible  through
MDCT to  distinguish  between  adenoma  and  focal  nodular  hyperplasia  without  central  scar.  Top  row:  Lesion  hyperintense  to  the  rest
of the  parenchyma  on  T2  with  discrete  restricted  diffusion  (DWI),  isointense  on  the  T1  in-phase  images  and  markedly  hypointense
on the  out-of-phase  sequence.  Bottom  row:  The  lesion  shows  important  enhancement  in  the  arterial  phase  and  is  isointense  on
the venous  and  hepatobiliary  phases.  It  is  important  to  remember  that  the  behavior  with  the  LS  contrast  agent  will  depend  on
the adenoma  subtype.  In  this  case,  the  distinction  between  focal  nodular  hyperplasia  was  made  due  to  the  important  signal  decay
observed in  the  out-of-phase  images,  characteristic  of  the  presence  of  intralesional  fat  in  adenomas.
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25 minVenousArterialPlain T1
In-phaseT2 Out-of-phaseDiffusion
Figure  6  Metastasis.  A  61-year-old  woman  with  a  history  of  cancer  of  the  left  breast.  Follow-up  ultrasound  identiﬁed  multiple
dispersed focal  lesions  in  the  hepatic  parenchyma.  MR  was  done  to  improve  characterization.  Top  row:  The  presence  of  multiple
rounded images  of  diffuse  distribution,  hypointense  on  T1  and  hyperintense  on  T2  and  diffusion  (DWI),  with  no  signal  decay  in  the
out-of-phase  sequence.  Bottom  row:  In  the  dynamic  sequences  with  gadoxetic  acid,  said  lesions  present  with  ring  enhancement  on
the arterial  phase  and  centripetal  ﬁll-in  on  the  later  phases.  The  lesions  are  observed  to  be  hypointense  on  the  hepatobiliary  phase
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ddue to  the  absence  of  hepatocytes.  In  addition,  other  lesions  a
the vertebral  bodies  and  paravertebral  muscles.  Data  are  relate
or  well  differentiated.34,35 In  this  setting,  the  recommen-
dation  is  to  look  for  other  signs  that  support  HCC  diagnosis,
such  as:  absence  of  a  central  scar,  a  nodule-in-nodule  image,
presence  of  a  hypointense  ring,  hyperintensity  in  the  diffu-
sion  sequences  because  of  its  restriction  and/or  signal  loss
(hypointensity)  in  the  out-of-phase  sequences  due  to  the
presence  of  intralesional  fat.36
The  fact  that  the  presence  of  certain  factors  can  limit
the  efﬁcacy  of  the  hepatobiliary  phase  in  lesion  detec-
tion  and  characterization  should  also  be  considered.  Those
patients  with  important  hepatic  dysfunction  or  cholesta-
sis  may  show  a  limited  concentration  of  the  hepatobiliary
agents.37 Recent  studies  report  that  there  is  a  decrease  in
the  diagnostic  performance  of  LS  contrast  media  when  cir-
rhosis  becomes  more  severe,  due  to  reduced  enhancement
in  the  hepatocellular  phase.38
Differential diagnosis
The  main  usefulness  of  the  studies  with  LS  contrast  media
is  the  improved  characterization  of  focal  lesions,  particu-
larly  the  distinction  between  benign  and  malignant  tumors.
Nevertheless,  it  is  not  recommended  that  a  hepatic  focal
lesion  study  protocol  only  include  the  hepatobiliary  phase,
given  that  all  the  lesions  that  are  not  composed  of  hepato-
cytes  will  behave  as  hypointense  ones.  Therefore,  in  order
to  avoid  incorrect  diagnoses,  it  is  important  to  be  familiar
with  the  lesions  that  will  have  hypotensive  behavior  in  the
hepatobiliary  phase  with  these  types  of  media  due  to  the
histologic  lack  of  functioning  hepatocytes.  The  distinction
p
q
r
tentiﬁed  that  have  similar  characteristics  and  enhancement  of
 metastasis.
etween  them  will  depend  on  the  analysis  in  conjunction
ith  all  the  sequences,  behavior  on  T1  and  T2,  fat  satu-
ation,  dual  echo,  diffusion,  and  perfusion  characteristics;
n  other  words,  if  there  is  arterial  or  venous  enhancement,
he  presence  or  not  of  washout,  the  type  of  enhancement
central  or  peripheral),  and  the  presence  or  not  of  cap-
ule.  The  MR  characteristics  of  the  different  focal  lesions
re  summarized  in  Table  1  and  Figures  3--6.
imitations
here  is  still  a  group  of  patients  in  whom  the  use  of  this
ype  of  contrast  medium  is  limited.  This  is  particularly
rue  in  patients  with  liver  dysfunction  (hyperbilirubine-
ia  >  3  mg/dL),  as  well  as  in  patients  with  focal  lesions
hose  vascular  permeability  is  to  be  evaluated,  especially
ortal  permeability,  due  to  the  low  volume  of  contrast
edium  employed.  It  is  also  true  for  HCC  patients  in  the
ost-ablation  follow-up  period,  in  the  abovementioned  indi-
iduals  with  well  differentiated  HCC  that  can  accumulate
he  contrast  medium  in  the  late  hepatobiliary  phases,  and
n  patients  with  rapid-ﬁlling  hemangiomas.7 A  joint  overall
nalysis  of  the  MR  characteristics  of  the  lesion  in  the  dif-
usion  sequences  and  its  behavior  on  T2  can  be  useful  in
istinguishing  between  these  entities.
Respiratory  artifacts.  Triple  acquisition  of  the  arterial
hase  with  a  single  apnea  has  been  shown  to  provide  ade-
uate  images  in  the  majority  of  patients  that  experience
espiratory  movement  artifacts  in  the  arterial  phase  with
he  use  of  a liver-speciﬁc  agent.39
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Other  points  to  consider  are  cost  (up  to  3  times  higher),
he  impact  of  examination  time  (study  lasting  20  min
onger),  and  the  potential  lower  enhancement  in  the  arterial
hase  with  the  use  of  the  approved  doses  (0.025  mmol/kg).3
onclusions
he  recent  introduction  of  LS  contrast  agents  in  the  evalu-
tion  of  hepatic  focal  lesions  is  an  additional  complement
hat  is  potentially  useful  in  undetermined  lesions,  whether
n  tumors  >  2  cm  with  uncharacteristic  behavior  in  conven-
ional  gadolinium-enhanced  multiphase  studies  or  computed
omography,  or  in  lesions  <  2  cm  in  patients  with  underlying
epatopathy  in  whom  early  and  accurate  detection  of  HCC
s  essential.
Therefore,  even  though  the  role  of  this  type  of  contrast
edium  must  still  be  deﬁned  through  clinical  trials  with
arger  numbers  of  patients,  and  especially  in  patients  with
dvanced  cirrhosis,  its  use  can  aid  in  improving  diagnostic
ensitivity  and  speciﬁcity,  when  it  is  compared  with  the  per-
ormance  of  the  conventional  strategies  in  these  groups  of
atients.
inancial disclosure
o  ﬁnancial  support  was  received  in  relation  to  this  article.
onﬂict of interest
he  authors  declare  that  there  is  no  conﬂict  of  interest.
eferences
1. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior
to helical CT for detection of HCC prior to liver transplantation:
An explant correlation. Hepatology. 2003;38:1034--42.
2. Rode A, Bancel B, Douek P, et al. Small nodule detection in
cirrhotic livers: Evaluation with US, spiral CT, and MRI and corre-
lation with pathologic examination of explanted liver. J Comput
Assist Tomogr. 2001;25:327--36.
3. Kim YK, Kim CS, Chung GH, et al. Comparison of gadobe-
nate dimeglumine-enhanced dynamic MRI and 16-MDCT for the
detection of hepatocellular carcinoma. AJR Am J Roentgenol.
2006;186:149--57.
4. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic
and economic impact of contrast imaging techniques in the
diagnosis of small hepatocellular carcinoma in cirrhosis. Gut.
2010;59:638--44.
5. McGlynn KA, London WT. Epidemiology and natural history of
hepatocellular carcinoma. Best Pract Res Clin Gastroenterol.
2005;19:3--23.
6. Kudo M. Real practice of hepatocellular carcinoma in Japan:
Conclusions of the Japan Society of Hepatology 2009 Kobe
Congress. Oncology. 2010;78 Suppl 1:180--8.
7. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma
and hepatitis B virus. A prospective study of 22 707 men in
Taiwan. Lancet. 1981;2:1129--33.
8. Bruix J, Sherman M, American Association for the Study of Liver
Diseases. Management of hepatocellular carcinoma: An update.
Hepatology. 2011;53:1020--2.
9. European Association For The Study Of The Liver; Euro-
pean Organisation For Research And Treatment Of Cancer.
2P.E.  Cossio-Torrico  et  al.
EASL-EORTC clinical practice guidelines: Management of hepa-
tocellular carcinoma. J Hepatol. 2012;56:908--43.
0. Omata M, Lesmana LA, Tateishi R, et al. Asian Paciﬁc Associa-
tion for the Study of the Liver consensus recommendations on
hepatocellular carcinoma. Hepatol Int. 2010;4:439--74.
1. Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acid-
enhanced hepatobiliary phase MR imaging in the diagnosis of
hepatocellular carcinoma. Radiology. 2010;255:459--66.
2. Golﬁeri R, Renzulli M, Lucidi V, et al. Contribution of the hepa-
tobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI
in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.
Eur Radiol. 2011;21:1233--42.
3. Haradome H, Grazioli L, Tinti R, et al. Additional value of gadox-
etic acid-DTPA-enhanced hepatobiliary phase MR imaging in the
diagnosis of early-stage hepatocellular carcinoma: Comparison
with dynamic triple-phase multidetector CT imaging. J Magn
Reson Imaging. 2011;34:69--78.
4. Van Beers B, Pastor C, Hussain H. Primovist, Eovist: What to
expect? J Hepatol. 2012;57:421--9.
5. Ringe K, Husarik D, Sirlin C, et al. Gadoxetate disodium-
enhanced MRI of the liver: Part 1, Protocol optimization and
lesion appearance in noncirrhotic liver. AJR Am J Roentgenol.
2010;195:13--28.
6. Zech C, Bartolozzi C, Bioulac- Sage P, et al. Consensus report
of the Fifth International Forum for Liver MRI. AJR Am J
Roentgenol. 2013;201:97--107.
7. Cruite I, Shroeder M, Merkle E, et al. Gadoxetate disodium-
enhanced MRI of the liver: Part2, protocol optimization and
lesion appearance in the cirrhotic liver. AJR Am J Roentgenol.
2010;195:29--41.
8. Feuerlein S, Boll D, Gupta R, et al. Gadoxetate disodium-
enhanced hepatic MRI: Dose-dependent contrast dynamics of
hepatic parenchyma and portal vein. AJR Am J Roentgenol.
2011;196:W10--24.
9. Kim T, Lee K, Jang H, et al. Analysis of gadobenato dimegumine-
enhanced MR ﬁndings for characterizing small (1-2 cm)  hepatic
nodules in patients at high risk for hepatocellular carcinoma.
Radiology. 2011;259:730--8.
0. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and stag-
ing of hepatocellular carcinoma: Part I. Development, growth,
and spread: Key pathologic and imaging aspects. Radiology.
2014;272:635--54.
1. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and stag-
ing of hepatocellular carcinoma: Part II. Extracellular agents,
hepatobiliary agents, and ancillary imaging ﬁndings. Radiology.
2014;273:30--50.
2. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nod-
ules 20 mm or smaller in cirrosis: Prospective validation of the
noninvasive diagnostic criteria for hepatocellular carcinoma.
Hepatology. 2008;47:97--104.
3. Matsui O, Kobayashi S, Sanada J, et al. Hepatocellular nodules in
liver cirrhosis: Hemodynamic evaluation (angiography-assisted
CT) with special reference to multi-step hepatocarcinogenesis.
Abdom Imaging. 2011;36:264--72.
4. Kim S, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus
triple-phase MDCT for the preoperative detection of Hepatocel-
lular carcinoma. AJR Am J Roentgenol. 2009;192:1675--81.
5. Golﬁeri R, Renzulli M, Lucidi V, et al. Contribution of the hepa-
tobiliary phase of Gd-EOB-DTPA- enhanced MRI to dynamic in
the detection of hypovascular small (≤ 2 cm)  HCC in cirrhosis.
Eur Radiol. 2011;21:1233--42.
6. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual
comparison of gadoxetate disodium-enhanced MR imaging
and 64-section multidetector CT in the detection of hepa-
tocellular carcinoma in patients with cirrhosis. Radiology.
2010;256:806--16.
7. Bartolozzi C, Battaglia V, Bargellini I, et al. Contrast-enhanced
magnetic resonance imaging of 102 nodules in cirrhosis:
for  f
3
3
3
3
3
4
4
4Liver-speciﬁc  gadoxetic  acid-enhanced  magnetic  resonance  
Correlation whit histological ﬁndings on explanted livers.
Abdom Imaging. 2013;38:290--6.
28. Pugacheva O, Matsui O, Kozaka K, et al. Detection of small
hypervascular hepatocellular carcinomas buy EASL criteria:
Comparison with double-phase CT during hepatic arteriography.
Eur J Radiol. 2011;80:e201--6.
29. Inoue T, Hyodo T, Murakami T, et al. Hypovascular hepatic nod-
ules showing hypointense on the hepatobiliary-phase image
of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular
hepatocellular carcinoma: A nationwide retrospective study
on their natural course and risk factors. Dig Dis. 2013;31:
472--9.
30. Kim YK, Lee WJ, Park MJ, et al. Hypovascular hypointense
nodules on hepatobiliary phase gadoxetic acid--enhanced MR
images in patients with cirrhosis: Potential of DW imaging in pre-
dicting progression to hypervascular HCC. Radiology. 2012;265:
110--4.
31. Kudo M. Advances in liver ﬁbrosis imaging and hepatocellu-
lar carcinoma: Update in 2013. Oncology. 2013;84 Suppl 1:
1--2.
32. Han K, Kudo M, Ye S, et al. Liver cancer study group of Japan,
48th annual meeting, Kanazawa, July 2012. Oncology. 2013;84
Suppl 1:21--7.
33. Kitao A, Matsui O, Yoneda N, et al. The uptake transporter
OATP8 expression decreases during multistep hepatocarcino-
genesis: Correlation with gadoxetic acid enhanced MR imaging.
Eur Radiol. 2011;21:2056--66.
34. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3
determines uptake of Gd-EOB-DTPA in hepatocellular carci-
noma. J Gastroenterol. 2009;44:793--8.
4ocal  lesion  evaluation  275
5. Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN. Hyperintense HCC
on hepatobiliary phase images of gadoxetic acid-enhanced MRI:
correlation with clinical and pathological features. Eur J Radiol.
2012;81:3877--82.
6. Suh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW. Differen-
tiation of hepatic hyperintense lesions seen on gadoxetic acid-
enhanced hepatobiliary phase MRI. AJR. 2011;197:W44--52.
7. Higaki A, Tamada T, Sone T, et al. Potential clinical
factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-
enhanced MR imaging. Magn Reson Imaging. 2012;30:689--93.
8. Kim AY, Kim YK, Lee MW, et al. Detection of hepatocellular car-
cinoma in gadoxetic acid-enhanced MRI and diffusion-weighted
MRI with respect to the severity of liver cirrhosis. Acta Radiol.
2012;53:830--8.
9. Pietryga JA, Burke LM, Marin D, et al. Respiratory motion
artifact affecting hepatic arterial phase MR imaging with gadox-
etate disodium: Examination recovery with a multiple arterial
phase acquisition. Radiology. 2014;271:426--34.
0. Cogley J, Miller F. MR imaging of benign focal liver lesions. Radiol
Clin North Am.  2014;52:657--82.
1. Van Kessel C, Boer E, Ten Kate F, et al. Focal nodular hyper-
plasia: Hepatobiliary enhancement patterns on gadoxetic-acid
contrast-enhanced MRI. Abdom Imaging. 2013;38:490--501.
2. Purysko A, Remer E, Coppa C, et al. Characteristics and distin-
guishing features of hepatocellular adenoma and focal nodular
hyperplasia on gadoxetate disodium-enhanced MRI. AJR Am J
Roentgenol. 2012;198:115--23.
3. Grazioli L, Olivetti L, Mazza G, et al. MR imaging of hepatocellu-
lar adenomas and differential diagnosis dilemma. Int J Hepatol.
2013:1--20.
